CRH (CRH) H2 2010 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2010 earnings summary
19 Nov, 2026Executive summary
2010 results broadly met guidance as like-for-like sales declines moderated through the year; Q4 like-for-like sales fell ~2%, versus 10% in H1.
Operational savings, pricing actions and cash discipline supported resilience through a difficult construction-market downturn.
Financial highlights
Reported sales declined 1%, while ongoing sales fell 7%; EBITDA was €1.6bn, down 10%, with EBITDA margin down 1% YoY.
Operating profit declined ~27%; earnings fell 31% to €0.613 per share.
Profit before tax was €658m before impairments and €534m after €124m of impairments; the latter was within the €520m–€550m guidance range.
Operating cash inflow was just under €700m; working capital generated €256m, while capital expenditure was €466m.
Outlook and guidance
2011 outlook called for decent like-for-like revenue growth, assuming no major market dislocations; price progress was key to revenue growth and recovering higher input costs.
2011 acquisitions were expected to add €600m in sales from 2010 deals, at an expected margin of 6%–7%.
Capital expenditure was expected to increase from 2010, but remain tightly controlled; the Ukraine cement plant was due to complete later in 2011.
Tax rate was expected to edge up toward 20% in 2011, depending on the geographic mix of profits.
Price strategies were being implemented across businesses; management expected to be ahead on price-cost spread if elevated crude prices did not persist.
Latest events from CRH
- Strong organic profit growth and cash generation cut year-end net debt below 3x EBITDA.CRH
H2 2015 - Strong growth and cash generation cut leverage to 1.7x while supporting further growth.CRH
H2 2016 - €3.3bn EBITDA, stronger margins and returns, and major acquisitions positioned for further growth.CRH
H2 2017 - U.S. momentum and cost actions supported 2013 progress as net debt fell EUR 519m.CRH
H2 2012 - H2 momentum improved as portfolio actions and disciplined investment set up a moderate 2014 recovery.CRH
H2 2013 - EBITDA rose 11% in 2014; 2015 priorities were growth, integration and debt reduction.CRH
H2 2014 - Sales rose 5% and EBITDA reached €1.66bn as margins proved resilient.CRH
H2 2011 - Q3 EBITDA held near prior year; FY26 guidance is $7.8B–$8.0B amid cost and residential headwinds.CRH
Q3 2026 - Q2 2026 saw strong growth, margin gains, and the Arcosa deal, supporting a positive outlook.CRH
Q2 2026